Bath & Body Works (NYSE: BBWI) reported second-quarter adjusted earnings per share of $0.62, significantly beating the analyst consensus estimate of $0.24. The Columbus, Ohio-based retailer posted quarterly sales of $1.514 billion, which also exceeded the consensus estimate of $1.497 billion.

The earnings result represents a 158.33% beat against the street estimate and marks a 67.57% increase from the $0.37 per share reported in the same period last year. Revenue declined 2.26% year-over-year from $1.549 billion, but the top-line performance still surpassed analyst expectations by 1.15%.

Strategic Progress and Product Innovation

Management highlighted tangible progress with its "Consumer First" formula, citing sequential improvement in Body Care, a return to growth in digital sales, and accelerated expansion in alternative distribution channels. The launch of the Fruit Fusion franchise exceeded sales expectations and achieved a higher average unit revenue (AUR) than core assortments. The company also announced its exit from the Home Care category, which represents less than 1% of annual sales, to focus resources on high-growth hero categories.

Revised Full-Year Guidance

Based on Q2 outperformance, Bath & Body Works narrowed its full-year net sales guidance to a decline of 4% to 2.5% (previously down 5% to 3%). Adjusted earnings per diluted share guidance was raised to $2.60 to $2.80, up from the prior range of $2.00 to $2.25.

The updated outlook reflects the benefit of approximately $80 million in tariff refunds recognized in Q2, partially offset by forward tariff pressure and input cost inflation estimated at $30 million. Additionally, the company plans to invest approximately $35 million into marketing efforts under the Consumer First strategy.

Analyst Ratings and Price Targets

Market sentiment remains mixed among top analysts despite the strong earnings beat. Wells Fargo analyst Ike Boruchow maintains an Overweight rating with a price target of $26, citing an accuracy rate of 72%. Conversely, Goldman Sachs analyst Kate McShane downgraded the stock to Sell with a target of $19.

What the Numbers Show

The Q2 adjusted EPS of $0.62 included a significant non-recurring benefit from $80 million in tariff refunds, which contributed approximately 530 basis points to merchandise margin. Excluding this benefit, adjusted EPS would have been $0.31, still beating the high end of the company's internal guidance range ($0.20-$0.25) by $0.06. This divergence highlights that while operational improvements are underway, the reported earnings beat was materially amplified by one-time tax relief rather than pure organic margin expansion.

Share Price and Dividend Action

Bath & Body Works shares fell 8.3% to close at $17.58 on Tuesday prior to the earnings release. On Aug. 7, the company declared a regular quarterly dividend of $0.20 per share. Free cash flow guidance for FY26 was raised to approximately $650 million, up from the prior guide of $600 million, driven by higher earnings expectations and lower capital expenditures.

Bath & Body Works (NYSE: BBWI) raised its fiscal 2026 adjusted earnings per share guidance to a range of $2.60 to $2.80, surpassing the $2.65 analyst estimate. The company also narrowed its full-year net sales outlook, signaling tighter control over revenue expectations.

The revised sales guidance now projects net sales between $6.999 billion and $7.109 billion, up from the previous range of $6.963 billion to $7.109 billion. This update beats the $7.095 billion analyst estimate for the period. The adjustment reflects improved profitability expectations despite ongoing top-line pressures in the retail sector.

Guidance Revision Details

In addition to the adjusted metrics, Bath & Body Works clarified that no share repurchases are assumed in this outlook. Furthermore, management forecasts generating approximately $650 million in free cash flow for fiscal 2026.

Q2FY26 Results

For the second quarter ended August 1, 2026, net sales totaled $1,514 million, a decrease of 2.3% from $1,549 million in the same period last year. Reported earnings per diluted share were $0.58, up from $0.30 in Q2FY25. Adjusted earnings per diluted share reached $0.62, compared to $0.37 in the prior year period.

Operating income for the quarter was $216 million, an increase from $157 million in Q2FY25. Net income rose to $118 million from $64 million previously. The reported results included aggregate pre-tax costs of $9 million associated with business transformation activities. Excluding this item, adjusted operating income was $225 million.

Notably, the quarter included approximately $80 million of tariff refunds received. Excluding this benefit, second quarter 2026 adjusted earnings per diluted share would have been $0.31. Despite the overall sales decline, the company delivered growth in Direct net sales, marking the first direct net sales growth since 2021.

Q3FY26 Outlook

For the third quarter of 2026, the company is forecasting net sales to decline between 5% and 2.5% compared to $1,594 million in the third quarter of 2025. Third quarter 2026 earnings per diluted share is expected to be between $0.05 and $0.10, down from $0.37 in the same period last year. Adjusted earnings per diluted share for Q3FY26 is projected at $0.07 to $0.12, compared to $0.35 in Q3FY25.

What the Numbers Show

The revision reflects a strategic recalibration rather than a broad-based improvement in volume. By narrowing the sales decline range and raising the floor to $6.999 billion against a base of $7,291 million in FY25, the company signals tighter control over its top-line trajectory despite challenging conditions. The divergence between the raised adjusted EPS ($2.60-$2.80) and the higher GAAP EPS ($3.13-$3.33) highlights the impact of specific adjustments on reported profitability. The forecast of $650 million in free cash flow provides a concrete liquidity benchmark for investors, anchoring the profitability gains in actual cash generation capability.